Glycoprotein IIb/IIIa inhibitors for heart attack and unstable angina

References

Citations

1. American College of Cardiology (ACC) and American Heart Association (AHA) (2002). Guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction. Report of the ACC/AHA Task Force on Practice Guidelines. Available online: http://www.acc.org/clinical/topic/topic.htm#guidelines.

2. Lincoff AM, et al. (1999). Complementary clinical benefits of coronary artery stenting and blockage of platelet glycoprotein IIb/IIIa receptors. New England Journal of Medicine, 341(5): 319–327.

3. Brown DL, et al. (2001). Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. American Journal of Cardiology, 87(5): 537–541.

4. De Luca G, et al. (2005). Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. JAMA, 293(14): 1759–1765.

5. O'Rourke RA, et al. (2001). New approaches to diagnosis and management of unstable angina and non–ST-segment elevation myocardial infarction. Archives of Internal Medicine, 161(5): 674–682.

Author:	Robin Parks, MS	Last Updated: May 14, 2007
Medical Review:	Caroline S. Rhoads, MD - Internal Medicine Stephen Fort, MD, MRCP, FRCPC - Interventional Cardiology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.